United States securities and exchange commission logo





                           May 18, 2022

       Stephen Brady
       Chief Executive Officer
       Tempest Therapeutics, Inc.
       7000 Shoreline Court; Suite 275
       South San Francisco, CA 94080

                                                        Re: Tempest
Therapeutics, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed May 16, 2022
                                                            File No. 333-264989

       Dear Mr. Brady:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Gary
Guttenberg at (202) 551-6477 with any questions.




                           Sincerely,


                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Michael Mencher